News
Press ReleaseRevive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.
TORONTO, Feb. 12, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the “LOI”) with Psilocin Pharma Corp. (“Psilocin”), an arm’s length party incorporated pursuant...
Revive Therapeutics Announces Brokered Private Placement of up to $2 million
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 11, 2020 - Revive Therapeutics Ltd. (“Revive” or the “Company”), a cannabis life sciences company...
Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing
TORONTO, Feb. 10, 2020 - Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has entered into a supply and collaboration agreement (the...
Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units
TORONTO, Feb. 05, 2020 - Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units (the...
Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
TORONTO, Jan. 20, 2020 - Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company’s...
Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases
TORONTO, Jan. 06, 2020 - Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’s clinical...